{"id":6969,"date":"2026-08-24T12:37:16","date_gmt":"2026-08-24T12:37:16","guid":{"rendered":"https:\/\/www.paytmmoney.com\/blog\/?p=6969"},"modified":"2026-08-24T12:38:49","modified_gmt":"2026-08-24T12:38:49","slug":"symbiotec-pharmalab-ipo-review","status":"publish","type":"post","link":"https:\/\/www.paytmmoney.com\/blog\/symbiotec-pharmalab-ipo-review\/","title":{"rendered":"Symbiotec Pharmalab IPO Review: Key Details,Company Overview & Financials"},"content":{"rendered":"

Symbiotec Pharmalab IPO is a book-built issue worth \u20b91,757 crore, comprising a fresh issue of 0.15 crore shares aggregating to \u20b9150 crore and an offer for sale of 1.63 crore shares worth \u20b91,607 crore. The IPO will be open for subscription from August 24 to August 27, 2026, with allotment expected on August 28 and tentative listing on NSE and BSE on September 1, 2026.\u00a0<\/span><\/p>\n

The price band has been fixed at \u20b9938 to \u20b9988 per share, while the lot size is 15 shares. Retail investors need a minimum investment of \u20b914,820 at the upper price band. Up to 33,408 shares are reserved for employees at a \u20b990 discount. JM Financial Ltd. is the book-running lead manager, while MUFG Intime India Pvt. Ltd. is the registrar.<\/span><\/p>\n

Company Overview<\/b><\/h2>\n

Symbiotec Pharmalab Ltd. is a research and development-focused pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. With over three decades of industry experience, the company has developed an integrated manufacturing platform serving pharmaceutical and nutraceutical customers globally.<\/span><\/p>\n

Its portfolio includes more than 60 corticosteroid and steroidal-hormone APIs, including Hydrocortisone, Betamethasone, Methylprednisolone, Progesterone, Estrogen and Testosterone. These products are used across therapeutic areas such as respiratory care, dermatology, pain management, oncology and women’s health. In Fiscal 2026, the company held global volume market shares of 38.2% in corticosteroid APIs and 23.8% in steroidal-hormone APIs, according to the F&S Report.<\/span><\/p>\n

Symbiotec operates manufacturing facilities in Madhya Pradesh and has capabilities in chemical synthesis, fermentation and complex injectables. It also provides contract development and manufacturing services to pharmaceutical and nutraceutical companies. As of March 31, 2026, the company served more than 200 customers across over 40 countries.<\/span><\/p>\n

Its R&D capabilities are supported by 156 scientists and engineers and three dedicated R&D centres in Indore.<\/span><\/p>\n

IPO Details<\/b><\/h2>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Particulars<\/th>\nDetails<\/th>\n<\/tr>\n<\/thead>\n
IPO Date<\/td>\n24 to 27 Aug, 2026<\/td>\n<\/tr>\n
Allotment<\/td>\nFriday, Aug 28, 2026<\/td>\n<\/tr>\n
Listing Date<\/td>\nTuesday, Sep 1, 2026<\/td>\n<\/tr>\n
Face Value<\/td>\n\u20b92 per share<\/td>\n<\/tr>\n
Price Band<\/td>\n\u20b9938 to \u20b9988<\/td>\n<\/tr>\n
Lot Size<\/td>\n15 Shares<\/td>\n<\/tr>\n
Issue Type<\/td>\nBookbuilding IPO<\/td>\n<\/tr>\n
Sale Type<\/td>\nFresh capital cum OFS<\/td>\n<\/tr>\n
Total Issue Size<\/td>\n1,77,86,442 shares (agg. up to \u20b91,757 Cr)<\/td>\n<\/tr>\n
Fresh Issue<\/td>\n15,21,261 shares (agg. up to \u20b9150 Cr)<\/td>\n<\/tr>\n
Offer for Sale<\/td>\n1,62,65,181 shares (agg. up to \u20b91,607 Cr)<\/td>\n<\/tr>\n
Shareholding Pre-Issue<\/td>\n6,16,81,496 shares<\/td>\n<\/tr>\n
Shareholding Post-Issue<\/td>\n6,32,02,757 shares<\/td>\n<\/tr>\n
Listing Exchange<\/td>\nBSE, NSE<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

(Compiled from RHP and market updates)<\/span><\/i><\/span><\/p>\n

Industry Context<\/b><\/h2>\n
    \n
  • The global pharmaceutical industry continues to expand across small molecules and biologics. Small molecules remained the larger segment in 2025, while biologics are projected to grow faster, supported by advances in targeted therapies, biosimilars and complex disease treatments.<\/span><\/li>\n
  • India remains a major global pharmaceutical manufacturing hub, supplying generic medicines to more than 200 countries. Its manufacturing scale, regulatory capabilities, skilled workforce and cost advantages support its position across APIs and finished pharmaceutical products.<\/span><\/li>\n
  • India\u2019s API exports increased from US$4.2 billion in 2020 to US$4.9 billion in 2025 and are projected to reach US$6.4 billion by 2030, supported by growing demand from regulated and emerging markets.<\/span><\/li>\n
  • India is working to strengthen domestic fermentation capabilities after production of several key fermentation-based products shifted overseas. Government initiatives, including production-linked incentives, infrastructure development and technology partnerships, aim to reduce dependence on imported APIs and intermediates.<\/span><\/li>\n
  • India\u2019s established presence in regulated markets supports its role as a global pharmaceutical supplier. Indian companies accounted for 48% of USDMF submissions in Q1 2025, highlighting the country\u2019s regulatory experience and manufacturing capabilities.<\/span><\/li>\n<\/ul>\n

    Business Strengths<\/b><\/h2>\n
      \n
    • Symbiotec Pharmalab has a strong position in corticosteroid and steroidal-hormone APIs, with over 60 products and significant global market shares in key molecules such as Hydrocortisone, Testosterone and Methylprednisolone.<\/span><\/li>\n
    • The company has a vertically integrated manufacturing platform spanning API production, fermentation and complex injectables, with manufacturing capacities across chemical synthesis, fermentation and specialised injectable products.<\/span><\/li>\n
    • Its R&D capabilities support complex product development across organic chemistry, biotechnology and injectables. The company has developed advanced technologies, including double-chamber systems, to address specialised pharmaceutical applications.<\/span><\/li>\n
    • Symbiotec Pharmalab serves over 200 customers across more than 40 countries, including pharmaceutical companies in North America, Europe and Asia. Its customer base includes both domestic and international clients.<\/span><\/li>\n
    • The company has reported growth in revenue and EBITDA margins, supported by product mix, regulated-market supplies and operational efficiencies. It also has an experienced leadership team with substantial pharmaceutical industry expertise.<\/span><\/li>\n<\/ul>\n

      Business Risks<\/b><\/h2>\n
        \n
      • Symbiotec Pharmalab derives a substantial majority of its revenue from API sales, with its top five APIs contributing 62.27% of revenue from operations in Fiscal 2026. Any decline in demand or production disruption could affect performance.<\/span><\/li>\n
      • The company\u2019s manufacturing facilities are subject to regulatory inspections and customer audits. Any quality issues, manufacturing failures or inability to maintain required certifications could result in regulatory action, reputational damage and operational challenges.<\/span><\/li>\n
      • Export markets contributed 67.04% of revenue from operations in Fiscal 2026, with the company serving customers across more than 40 countries. Changes in regulations, trade policies, tariffs or foreign market conditions could affect international sales.<\/span><\/li>\n
      • Customer concentration remains a key risk, with the top 10 customers accounting for 57.59% of revenue from product sales in Fiscal 2026. Loss of key customers or lower orders could adversely affect revenue and financial performance.<\/span><\/li>\n
      • The company\u2019s manufacturing facilities and R&D centres are concentrated in Madhya Pradesh. Operational disruptions caused by natural events, infrastructure issues, regulatory changes, supply interruptions or other regional developments could affect production and business continuity.<\/span><\/li>\n<\/ul>\n

        Financial Performance<\/b><\/h2>\n

        Symbiotec Pharmalab Ltd. – Financials (\u20b9 in Million)<\/b><\/h3>\n

        <\/p>\n

        \n\n\n\n\n\n\n\n\n\n\n\n
        Particulars<\/th>\nFiscal 2026<\/th>\nFiscal 2025<\/th>\nFiscal 2024<\/th>\n<\/tr>\n<\/thead>\n
        Revenue from Operations<\/td>\n8,691.49<\/td>\n7,515.54<\/td>\n7,162.47<\/td>\n<\/tr>\n
        Net Worth<\/td>\n11,586.41<\/td>\n8,211.52<\/td>\n7,206.76<\/td>\n<\/tr>\n
        EBITDA<\/td>\n2,319.73<\/td>\n2,061.12<\/td>\n1,770.41<\/td>\n<\/tr>\n
        Profit \/ (Loss) After Tax (PAT)<\/td>\n1,099.03<\/td>\n967.85<\/td>\n1,000.55<\/td>\n<\/tr>\n
        PAT Margin (%)<\/td>\n12.60%<\/td>\n12.80%<\/td>\n13.83%<\/td>\n<\/tr>\n
        Return on Capital Employed (ROCE) (%)<\/td>\n11.56%<\/td>\n11.80%<\/td>\n14.03%<\/td>\n<\/tr>\n
        Return on Equity (%)<\/td>\n11.19%<\/td>\n12.66%<\/td>\n14.98%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

        <\/p>\n

        \u2190 Swipe horizontally to view full table \u2192<\/div>\n